Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
GW-0742
GW-0742 is a highly selective PPARdelta agonist related to Cardarine (GW-501516). It is being explored for its ability to enhance fatty acid oxidation and improve metabolic parameters. It remains a research chemical with no human clinical trials completed.
Risk Level
High RiskDifficulty
Advanced| CAS Number | 317318-84-6 |
| Molecular Formula | C21H17F4NO3S2 |
| Class | Other |
| Category | Fat Loss Agents |
Mechanism of Action
GW-0742 selectively activates PPARdelta nuclear receptors with greater potency and selectivity than GW-501516. Activation upregulates genes involved in fatty acid beta-oxidation, energy uncoupling, and lipid transport. It shifts substrate utilization toward fatty acids, increases HDL cholesterol, and reduces triglycerides in preclinical models. It may also reduce inflammation via NF-kB pathway modulation.
Dosing Research
No established human dosing. Animal research uses 1-10 mg/kg. Underground community references 10-20 mg/day. No human pharmacokinetic data or clinical trials. Duration and cycling protocols are entirely speculative.
Side Effects & Risks
Shares the PPARdelta-related cancer concerns observed with GW-501516 in rodent studies. No human safety data whatsoever. Potential risks include carcinogenesis, metabolic disruption, and liver stress. Considered high risk due to complete lack of human data.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.